ERBB2 and cancer: Recently, three studies showed that, by using the PAM50, MammaPrint, and BluePrint tests, despite the majority of luminal subtypes, HER2-low cancers also contain a small portion of the HER2-enriched subtype (3.5-3.6%) and basal-like(13.3–17.7%) subtypes [39].